Adjusted EBITDA reached $76M in Q2 2026, with revenue up 4% year-over-year, driven by improved payer mix, RCM collections, and higher acuity. Full-year EBITDA guidance is reaffirmed, and share repurchases continue as the company focuses on tele-hybrid medicine and acquisition opportunities.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.